1

2
Tarran Jones
Masayuki Tsuchiya, Koh Sato, Mary Margaret Bendig, Steven Tarran Jones, Jose William Saldanha: Reshaped human antibody to human interleukin-6 receptor. Chugai Seiyaku Kabushiki Kaisha, Foley & Lardner, January 20, 2009: US07479543 (96 worldwide citation)

A reshaped human antibody to the human IL-6R, comprising: (A) an L chain comprising, (1) a human L chain C region, and (2) an L chain V region comprising human L chain framework regions (FRs), and mouse L chain complementary determination regions (CDRs) of a momoclonal antibody to the IL-6 receptor ...


3

4
Tarran Jones
Neil I Goldstein, Nicholas A Giorgio, Steven Tarran Jones, Jose William Saldanha: Humanized anti-EGF receptor monoclonal antibody. ImClone Systems Incorporated, Kenyon & Kenyon, June 13, 2006: US07060808 (55 worldwide citation)

A nucleic acid is provided which encodes a humanized antibody or fragment thereof, which encodes a protein which binds to human EGF-receptor. Monoclonal antibody 225 is the complementary determining region (CDR) donor.


5
Tarran Jones
Britta Hardy, Steven Tarran Jones, Leah Klapper: Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency. CureTech, Mor Research Applications, Winston & Strawn, February 19, 2008: US07332582 (21 worldwide citation)

The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, and is capable of eliciting an anti-tumor effect upon administration t ...


6
Tarran Jones
Britta Hardy, Steven Tarran Jones, Leah Klapper: Humanized immunomodulatory monoclonal antibodies for the treatment of immunodeficiency. CureTech, Mor Research Applications, Winston & Strawn, July 19, 2011: US07981416 (9 worldwide citation)

The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect ...


7
Tarran Jones
Britta Hardy, Steven Tarran Jones, Leah Klapper: Human immunomodulatory monoclonal antibodies for the treatment of cancer. CureTech, Mor Research Application, Winston & Strawn, April 28, 2009: US07524498 (7 worldwide citation)

The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect ...


8
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams: Compositions and methods for binding sphingosine-1-phosphate. Lpath, BioTechnology Law Group, Daniel M Chambers, November 9, 2010: US07829674 (4 worldwide citation)

The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.


9
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Williams: Methods of using humanized antibodies and compositions for binding sphingosine-1-phosphate. Lpath, Acuity Law Group P C, Daniel M Chambers, September 27, 2011: US08025877 (2 worldwide citation)

The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases ...


10
Tarran Jones
Roger A Sabbadini, William A Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams: Compositions and methods for binding sphingosine-1-phosphate. Lpath, Acuity Law Group P C, Daniel M Chambers, September 27, 2011: US08026342 (1 worldwide citation)

The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.